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Abstract 
Many inherited metabolic disorders cause movement disorders in children.  This review focuses 
on chorea, dystonia, myoclonus, tremor, and parkinsonism.  Broad categories commonly 
responsible for pediatric movement disorders include mitochondrial disorders, organic 
acidemias, mineral metabolism and transport disorders, neurotransmitter diseases, purine 
metabolism disorders, lipid storage disorders, and disorders of creatine metabolism.  Each 
movement disorder can be caused by many different inherited metabolic disorders and several of 
the inherited metabolic disorders can cause multiple movement abnormalities.  Dietary 
modifications, medications, and increasingly specific therapy can improve outcomes in children 
with movement disorders caused by metabolic disorders.  Recognition and characterization of 
secondary movement disorders in children facilitate management of the abnormal movements 
and diagnosis, and possible treatment, of an underlying metabolic disorder.   
Introduction 
Many inborn errors of metabolism (IEM) cause movement disorders in children.
 1, 2
Movement is a complex task that requires proper functioning of many areas of the nervous 
system.  Any disturbance in the motor pathway from the central nervous system to muscle fibers 
can lead to abnormal movements.  IEM may cause localized or systemic dysfunction.  If the 
nervous system is involved, movement disorders are common. An individual IEM may be 
associated with more than one type of movement disorder.  Likewise, a specific movement 
disorder usually does not predict a particular IEM.
2
  While chronic movement disorders are more
common in children with IEM, acute presentation of movement abnormalities can occur such as 
abrupt onset dystonia.
3
  Conversely, children with abnormal involuntary movements due to a
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known IEM may experience acute worsening of symptoms such as potentially life-threatening 
status dystonicus with rhabdomyolysis.
4
Movement disorders covered in this review will include hyperkinetic movements (chorea, 
dystonia, myoclonus, and tremor) as well as hypokinetic movements (parkinsonism or 
hypokinetic rigid syndrome).  Broad categories under the umbrella of IEM commonly 
responsible for pediatric movement disorders include mitochondrial disorders, organic 
acidemias, mineral metabolism and transport disorders, neurotransmitter diseases, purine 
metabolism disorders, lipid storage disorders, and disorders of creatine metabolism.  Such 
diagnoses require screening of specific metabolites in urine, serum, and/or cerebrospinal fluid 
(CSF).  Results of this initial testing may lead to further biochemical analysis or genetic testing.  
Timely recognition of these underlying metabolic causes often allows disease-specific treatments 
and the best possible outcome for the affected child.
2
  Even with treatment, however, movement
disorders in patients with IEM rarely resolve completely and can cause life-long disability.   
Both IEM and movement disorders impact children’s quality of life (QOL).1  This impact
on quality of life has been suggested to be greater than that of other childhood chronic disorders.
1
As expected, increasing severity of movement disorder positively correlated with lower (QOL) 
scores.  Lower adaptive abilities were also linked to lower scores.  Unfortunately, few patients 
included in this QOL study received treatments for the abnormal movements.
1 
 While it is
suspected treatment improves QOL, this has not been formally quantified for the movement 
disorders in patients with IEM as a large group.  
Typically, treatment of underlying IEM consists of dietary modifications and possible 
addition of cofactors or supplements.  Better medical management options are increasing but 
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remain both elusive and often invasive.  Secondary therapy of the movement disorder may also 
benefit patients with IEM for both chronic movement abnormalities and acute presentations.  
Beyond lack of primary treatment, barriers to treating children with IEM-associated movement 
disorders include under-recognition of both pediatric movement disorders and individually rare 
IEM, delay in reaching a suspected IEM diagnosis, and inadequate access to secondary 
movement disorder treatment.
1, 5
Movement Disorders 
Chorea is characterized by brief random movements that are neither rhythmic nor 
stereotyped.  It occurs in injury to the striatum and subthalamic nucleus as well as widespread 
brain injury.
6
  Movements appear purposeless and affect any part of the body, including the face.
They can migrate from one side of the body to the other side and between upper limbs and lower 
limbs.  Motor impersistence can be observed with voluntary tongue protrusion.  Chorea occurs 
during both voluntary movement and with the child at rest.  Individuals with chorea may appear 
restless due to the constant movement. Chorea typically abates during sleep.  As patients become 
older, they may attempt masking the abnormal movements by incorporating them into a 
voluntary movement.
7
  Chorea is a prominent feature of glutaric aciduria type 1, glucose
transporter type 1 (GLUT1) deficiency, Wilson disease, neuronal brain iron accumulation 
disorders (NBIA), neurotransmitter diseases, and Lesch-Nyhan disease.
7,8
  A full list of disorders
associated with chorea is in Table 1.   
Dystonia is a manifestation of repetitive muscle contractions that are sustained at their 
peak.  These contractions lead to torsional postural changes.  Although classified as a 
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hyperkinetic movement disorder, dystonia often appears to be a postural abnormality than an 
involuntary movement, but both are possible.  While dystonia is often provoked by voluntary 
movement, which can be specific, more severe dystonia may persist at rest.  Dystonia is 
classified as focal (affecting a single body part), multifocal (affecting two or more noncontiguous 
regions) segmental (affecting two or more contiguous body parts), hemidystonia (affecting the 
arm and leg on one side of the body), and generalized (affecting one or both legs, the trunk, and 
another body part).
9, 10
  Dystonia localizes to the globus pallidus and striatum, even though
thalamic, cortical, and cerebellar injury likely contribute to the movement disorder.
11 
 Many
metabolic diseases have dystonia as a feature at some point during their course.  In children with 
IEM, dystonia is often a prelude to parkinsonism in later childhood and adolescence.  Focal, 
slowly progressive, and isolated dystonia is most likely to be caused by primary dopaminergic 
deficiencies (guanosine triphosphate (GTP) cyclohydrolase 1 deficiency and tyrosine 
hydroxylase deficiency).
12
  Abrupt onset, generalized dystonia can be caused by many different
metabolic abnormalities.  Some of the most frequent IEM causing dystonia are glutaric aciduria 
type 1 (GA1), Leigh syndrome, and other mitochondrial cytopathies.  Rare, but very treatable 
genetic causes of childhood dystonia include autosomal dominant GTP cyclohydrolase 1 
deficiency, tyrosine hydroxylase deficient dopa-responsive dystonia, and GLUT1 deficiency.
12
A more complete list of IEM associated with dystonia is found in Table 2.   
Myoclonus appears as a very quick and abrupt movement often described as “shock-like” 
in nature.  It can be rhythmic or non-rhythmic, and it is not incorporated into a voluntary 
movement.  There is a pause between individual myoclonic jerks.  Myoclonus can be 
generalized, focal, or multifocal.  It can be spontaneous or in response to a movement or 
sensation.
13
  Myoclonus is thought to be caused by injury to cortical, brainstem, or spinal cord
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gray matter and can be either epileptic or nonepileptic.
14
  Table 3 provides a list of IEM that can
have myoclonus as a feature.  Specific IEM that often cause myoclonus are mitochondrial 
encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy 
with ragged red fibers (MERRF), GM1 gangliosidosis, cerebral creatine deficiency syndrome 2 
(guanidinoacetate methyltransferase deficiency), GLUT1 deficiency, and Wilson disease.   
Tremor is rhythmic oscillation about a central point or position with a fixed frequency.   
The types of tremor are distinguished by timing and morphology.  Tremor may be resting, 
postural, action, or intention, affecting the extremities, trunk, head, and/or voice.
13
  It may be of
small or large amplitude (e.g. so-called “wing-beating” tremor seen in Wilson disease).  Tremor 
may be a manifestation of dystonia as well as cerebellar dysfunction.  Although it is a primary 
neurologic manifestation of Wilson disease, tremor is generally not the overarching neurologic 
symptom in pediatric IEM.
2  
See Table 4 for a compilation of conditions in which tremor can be
seen.  
Parkinsonism is defined by the presence of two or more of the following: resting tremor, 
bradykinesia, rigidity, and postural instability.  Hypokinetic rigid syndrome (HRS) is the 
preferred term for parkinsonism in children.
15
  HRS is caused by dopaminergic transmission
failure in the substantia nigra or striatum.  Compared to parkinsonism in adults, children with 
HRS rarely have resting tremor and more commonly have other forms of abnormal movements 
such as dystonia.
15
  HRS more commonly occurs in older children and adolescents than in infants
and toddlers where it is quite rare.  It also frequently develops as a secondary movement disorder 
after dystonia has been present for a few years.  Since HRS is rare in children, underlying 
metabolic disorders require exclusion regardless of age in the pediatric population.  Table 5 
contains a list of conditions that either present as or feature HRS in childhood. Within these, 
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Wilson disease, NBIA, and neuronal ceroid lipofuscinoses are the most common associated 
disorders.  
The remainder of this review will focus on several metabolic conditions that have 
movement disorders as a primary feature.  While several have movement disorders as a common 
presenting abnormality, all conditions discussed below have movement disorder as a major 
feature at some point in the disease course.   
Glutaric Aciduria Type 1 
Glutaric aciduria type 1 (GA1) is an autosomal recessive IEM caused by mutations in the 
glutaryl CoA dehydrogenase gene (GCDH).  Pathogenic mutations lead to a deficiency of 
glutaryl CoA dehydrogenase resulting in impaired catabolism of lysine, hydroxylysine, and 
tryptophan with resulting accumulation of 3-hydroxyglutaric acid and glutaric acid.  These 
metabolites, in excess, lead to neuronal death.
16
  Typical clinical presentation includes early
progressive macrocephaly and hypotonia after an initial normal period.
17
  Affected children often
have acute decompensation with encephalopathy by the age of two years.
18
  Triggers of the
decompensation are typically illness, though a trigger is not always identified.  During or shortly 
after the acute encephalopathic crisis, abnormal movements abruptly start.  Patients usually 
experience generalized dystonia, though focal and segmental dystonia are possible.
19
  The
dystonia is mobile in childhood but typically becomes fixed by adolescence.  Orofacial dystonia 
is prominent and typically occurs early, leading to speech and feeding difficulties.  Dystonia may 
co-exist with hypokinetic rigidity (parkinsonism) or chorea. The degree of disability is linked to 
the age and severity of acute decompensation.
19
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Treatments specific for patients with GA1 focus on normalizing metabolism and 
preventing recurrent acute encephalopathic episodes that can lead to further brain damage.  
Treatments include protein restriction and supplementation with carnitine and riboflavin.
20
Therapy does not reverse the neurologic damage causing the movement disorder, nor does it 
ameliorate an already existing movement disorder.  Medications that target the abnormal 
movements can be used.  Baclofen for dystonia, benzodiazepines for dystonia and chorea, 
trihexyphenidyl for dystonia, and botulism toxin injections for dystonia have all been used in 
patient with GA1. These treatments tend to have uncertain success.
21
GLUT1 Deficiency Syndrome 
Glucose transporter type 1 (GLUT1) deficiency syndrome classically has been 
characterized by infantile-onset epilepsy refractory to medication management, acquired 
microcephaly, developmental delays, hypotonia, spasticity, ataxia, and dystonia.
22
  Glut1
facilitates the transport of glucose across the blood-brain barrier, and symptoms result from this 
insufficient energy source to the brain.
23
Most patients with GLUT1 deficiency have a CSF to blood glucose ratio of <0.5.  If 
GLUT1 deficiency syndrome is suspected, the appropriate first test is obtaining CSF glucose and 
serum glucose simultaneously so that a ratio can be calculated.    Hypoglycorrhachia is the 
distinctive biomarker but can be present in other conditions such as infection. The cut-off value 
for hypoglycorrhachia seen in GLUT1 deficiency syndrome patients has liberalized over time, 
including higher values as the phenotype has expanded.
24
  Diagnosis is confirmed by the
presence of a heterozygous mutation in the SLC2A1 gene, which is typically de novo.  
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on February 19, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
Pathogenic mutations have not been found in all affected patients, so the lack of an identified 
mutation should not preclude a treatment trial.
25
As this condition has become more widely recognized, more phenotypes have been 
described.  GLUT1 deficiency syndrome clinical presentations now also include paroxysmal 
exertion-induced dyskinesia with or without seizures, choreoathetosis, alternating hemiplegia, 
intermittent ataxia, intermittent dystonia, and migraine.
25, 26
  Cognitive impairment varies widely
in affected patients.  Language delays are also possible either from cognitive delay or dysarthria.  
Severity of intellectual disability often positively correlates with that of other symptoms.
26
Movement disorders in GLUT1 deficiency syndrome patients often evolve in complexity 
and may include ataxia, dystonia, chorea, tremor, myoclonus, and HRS.  Movement 
abnormalities can be continuous or paroxysmal.  Acute presentation of dystonia has been 
reported.
3 
 While movement disorders may be present initially, epilepsy more frequently occurs
early in the disease course then gradually recedes, only to be replaced by abnormal involuntary 
movements.
27
Early diagnosis is important as treatment with the ketogenic diet or modified Atkins diet 
allows for an alternate energy source for the brain and subsequent improvement in seizures, 
abnormal movements, and other symptoms of the disease.
28
  Certain medications should be
avoided as they impair GLUT1 function, including phenobarbital, diazepam, chloral hydrate, 
tricyclic antidepressants, and caffeine.
29
  Secondary treatment of movement disorders can be
used in patients with GLUT1 deficiency with certain cautions.  Valproic acid used to treat 
myoclonus needs to be avoided in patients with GLUT1 deficiency as it increases the likelihood 
of Reye-like illness in patients on the ketogenic diet and may impair glucose transport.
30
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 Wilson Disease 
Wilson disease, otherwise known as hepatolenticular degeneration, is a copper transport 
disorder that is inherited in an autosomal recessive pattern.  Pathogenic variants in the ATP7B 
gene encoding copper transport ATPase-2 lead to disease.
31
  While certain populations have 
common pathogenic variants such as p.His1069Gln in Europeans (an amino acid substitution in a 
highly conserved motif close to the ATP-binding region) and p.Arg778Leu in Asian populations 
(an amino acid substitution in exon 8), over 800 mutations have been reported.
32, 33, 34
  Types of 
pathogenic variants include nonsense, missense, frameshift, splice site, and large deletions.  The 
Wilson Disease Mutation Database, curated at the University of Alberta, 
(http://www.wilsondisease.med.ualberta.ca/database.asp) contains documentation of the reported 
pathogenic variants as well as non-disease causing variants reported in the literature.  Copper 
transport ATPase-2 is involved in transporting copper from hepatocytes into bile.
31
   
Copper accumulation leads to cellular injury in the central nervous system, liver, and 
cornea.  Symptoms can be isolated to one of the affected organ systems or occur in any 
combination.  Significant phenotypic variability can be seen within families, and patients can 
present over a large age range from 3 to 50 years.
35
   
Young children typically present with hepatic failure and not neurologic symptoms.  
However, adolescents are more likely to present with neurologic symptoms and minimal signs of 
hepatic dysfunction.  Thus, adolescent patients often present with complaints of gait problems or 
changes in speech.  Over years, patients with Wilson disease develop various movement 
disorders, including chorea, dystonia, rigidity, tremor, and postural instability.  Prominent 
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features of Wilson disease include dysarthria, risus sardonicus (fixed pseudosmile), and 
inspiratory stridor all of which are caused by bulbar muscle dystonia.
36
  Status dystonicus has
been reported in children with Wilson disease which can be life threatening.
4
  Increased muscle
contractions overtime may progress to rhabdomyolysis with myoglobinuria and acute renal 
failure. Infection, medications or medication withdrawal typically triggers this deterioration.  
Other causes of discomfort such as constipation and gastroesophageal reflux need to be 
addressed aggressively during the episode.
3
  The nearly pathognomonic feature of Wilson
disease is the Kayser-Fleischer ring, a yellow-brown coloration of the limbus of the cornea 
caused by copper deposits in the Descemet membrane.
37
  This finding is almost always present in
patients with neurologic symptoms.  Psychiatric symptoms are also possible and may be present 
before neurologic abnormalities.   
Testing recommendations include obtaining serum copper, serum ceruloplasmin, and 
urine copper.  Most individuals with Wilson disease have low serum copper and ceruloplasmin 
with elevated urine copper.  Occasionally, serum and urine biochemical testing is inconclusive, 
so liver biopsy may be necessary to confirm the diagnosis.  Disease status can also be confirmed 
using molecular genetic testing, though delays in obtaining these results may lead to delay in 
treatment.
38
Early detection of Wilson disease is critical since early treatment can prevent permanent 
neurologic disorders and cirrhosis.
39
  The first-line treatment for individuals with Wilson disease
is the copper chelating agents D-penicillamine and trientine.
38
  Medical treatment increases
urinary excretion of copper with goals of five to ten times the normal urinary copper levels.  D-
penicillamine is typically the first agent used and must be given with pyridoxine.  However, it 
can have significant side effects that limit long-term use.  Patients taking this drug must have 
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regular monitoring for thrombocytopenia, aplastic anemia, and leukopenia.  Kidney injury can 
also occur leading to proteinuria, nephrotic syndrome, and Goodpasture syndrome.  Severe skin 
reactions are also possible.  While steroids can sometimes mitigate some side effect symptoms, 
D-penicillamine treatment must be stopped in a significant portion of patients.
39, 40
  The second-
line agent typically used is trientine.  This drug tends to be better tolerated but may be 
unavailable.
41
  Zinc supplementation interferes with copper absorption in the gastrointestinal
tract and can be used as first-line therapy, but is more often given after initial treatment with a 
chelating agent; zinc should not be used in conjunction with chelating agents.
42
  Other adjunctive
therapies include vitamin E supplementation to protect tissues from free radical damage and 
limiting intake of copper rich foods.
43
  Therapy needs to continue throughout the patient’s
lifespan, including during pregnancy.
38
  For patients who fail treatment with copper chelating
agents or zinc, liver transplantation is an option.  Liver transplantation early in disease 
management remains a controversial issue.
44
  Medical therapy for individual movement disorders
can also be used and deep brain stimulation has been reported as beneficial for severe tremor and 
dystonia in patients with Wilson disease.
45 
Leigh Syndrome 
Leigh syndrome, otherwise known as subacute necrotizing encephalomyelopathy, can be 
inherited in several patterns including autosomal recessive, X-linked, and maternal.  There are 
more than 50 nuclear-encoded genes and 14 mitochondrial-encoded genes that have been linked 
to Leigh syndrome.
46, 47
  The most common cause of nuclear-encoded Leigh syndrome is
pathogenic variants in the SURF1 gene, which accounts for approximately 10% of all cases.
48
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For maternally inherited forms of Leigh disease, the most common cause is pathogenic variants 
in the MT-ATP6 gene which occurs in roughly 50% of cases.
49
  Most of the other genetic 
etiologies are found in single family case reports and account for <5% of cases each.  The genes 
associated with Leigh syndrome encode proteins important in energy metabolism, and tissues 
with high energy requirements including the brain, heart, and liver are most often affected.
46, 47
  
Patients with Leigh syndrome typically present between 3 and 12 months, though adult 
presentations have also been reported.  Many patients present during or immediately after an 
acute illness with neurologic decompensation.  Acute presentation of dystonia is also possible.
3
  
The neurologic decompensation leads to developmental delays and regression in a step-wise 
fashion.  In between illnesses children are often stable and some may make developmental 
progress.  However, decline with eventual respiratory or cardiac failure is typical.
36
  Common 
neurologic abnormalities include hypotonia, spasticity, peripheral neuropathy, ataxia, and 
movement disorders including chorea, dystonia, and cogwheel rigidity.  Other manifestations of 
Leigh syndrome are cardiomyopathy, anemia, renal tubulopathy, liver dysfunction, ptosis, and 
myopathy.
46, 47
  The original criteria published in 1996 required the presence of a progressive 
neurologic disease with motor and intellectual developmental delays, involvement of the 
brainstem and/or basal ganglia, and elevated blood or CSF lactate levels.  These criteria also 
required individuals to have one of the following: characteristic neuroimaging findings, typical 
neuropathologic findings, or typical neuropathologic findings in a similarly affected sibling.
50
   
The characteristic neuroimaging findings seen with Leigh syndrome are bilateral 
symmetrical hypodensities on computed tomography (CT) or hyperintensities on T2-weighted 
magnetic resonance imaging (MRI) involving the brainstem and/or basal ganglia.  Cerebellar and 
cerebral atrophy can also be seen on MRI.  Another useful imaging modality is proton magnetic 
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resonance spectroscopy (MRS) for detection of elevated brain lactate levels seen in the basal 
ganglia, white matter, and/or brainstem.  Neuropathologic findings of Leigh syndrome are 
multiple symmetric necrotic lesions involving the basal ganglia, thalamus, brainstem, dentate 
nuclei, and optic nerves bilaterally.  The necrotic lesions typically have a spongiform appearance 
with demyelination, gliosis, and vascular proliferation with relative neuronal sparing.  Diagnostic 
criteria of Leigh syndrome have relaxed overtime with more recent diagnostic criteria no longer 
requiring elevated lactate levels as lactate levels can vary over time in a single patient.  As the 
etiology of Leigh syndrome has become more well established, the focus of diagnostic criteria 
has transitioned to presence of symptoms related to mitochondrial dysfunction, abnormal enzyme 
activity in either oxidative phosphorylation or the pyruvate dehydrogenase complex, and 
pathogenic variants in genes related to mitochondrial function.
51
Treatment of most causes of Leigh syndrome is largely supportive.  However, there is 
specific treatment for biotin-thiamine-responsive basal ganglia disease (caused by pathogenic 
variants in the SLC19A3 gene), biotinidase deficiency (caused by pathogenic variants in the BTD 
gene), and primary coenzyme Q10 deficiency (caused by pathogenic variants in the COQ2, 
COQ6, COQ8B, or PDSS2 genes).
46
  Biotin-thiamine-responsive basal ganglia disease is treated
by supplementation with biotin and thiamine.  If provided early in the disease course, biotin and 
thiamine can lead to partial or complete symptom resolution.
52
  Biotinidase deficiency is treated
by oral biotin replacement.  Individuals detected on newborn screening with replacement started 
in the neonatal period and lifelong treatment can remain symptom free.  Even patients treated 
after symptom onset often improve.
53
The natural history of certain forms of primary coenzyme Q10 deficiency is modifiable 
with high-dose oral coenzyme Q10.  Patients may not develop further neurologic symptoms after 
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supplementation is initiated.
54
  Treatment of all patients with Leigh syndrome, with and without
available primary treatments, focuses on adequate nutritional support, appropriate hydration, and 
avoidance of illness and other causes of stress.   
During acute exacerbations of acidosis, sodium bicarbonate or sodium citrate can be 
used.
46, 47
  Typical antiepileptic drugs are used to treat seizures with care to avoid valproic acid
and, if possible, barbiturates since these treatments interfere with mitochondrial respiratory chain 
function.
55
  Patients with Leigh syndrome should also avoid other drugs that interfere with
mitochondrial respiratory chain function, although toxicity related to many agents is relative and 
must be weighed against the risk of withholding the agent in question.  
Standard therapies are used to treat dystonia including baclofen, benzhexol, 
tetrabenazine, gabapentin, and botulinum toxin.  Dichloroacetate reduces lactate and was 
considered as a possible treatment for patients with lactic acidosis such as that seen in 
individuals with Leigh syndrome. However, during the clinical trial, patients experienced no 
clinical benefit and some developed peripheral neuropathy.  Current recommendation is to avoid 
dichloroacetate given the risk of peripheral neuropathy from either drug exposure or from 
exacerbation of the underlying risk of peripheral neuropathy.
56
Exposure to anesthesia needs to be carefully considered as inhaled anesthetics variably 
inhibit mitochondrial complex I activity, and respiratory function can be compromised leading to 
failure, which is a common cause of death in patients with Leigh syndrome.  Ultimately, 
however, surgical risks in individuals with Leigh syndrome is likely affected mostly by success 
in maintaining normal perfusion, oxygenation, temperature, and metabolic parameters, and 
providing adequate pain control peri-and post-operatively.
57
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Neurodegeneration with Brain Iron Accumulation 
Neurodegeneration with brain iron accumulation (NBIA) is a group of neurodegenerative 
disorders characterized by the accumulation of iron in the basal ganglia and axonal spheroids in 
the central nervous system.  Frequently, iron accumulates in the globus pallidus and substantia 
nigra.  Currently, there are ten recognized forms of NBIA (see Table 6) The known genes 
associated with NBIA play a part in energy and lipid metabolism as well as oxidative stress.  
These ten conditions account for most cases of NBIA, though 35-40% of patients with NBIA 
cannot be diagnosed with a specific form based on clinical criteria or genetic testing.
58
  All forms
of NBIA are inherited in an autosomal recessive pattern except for BPAN, which is inherited in 
an X-linked dominant pattern with suspected male lethality, and neuroferritinopathy, which is 
inherited in an autosomal dominant pattern.
58, 59
  PKAN, associated with about 50% of NBIA
cases, is the most common form followed by PLAN, MPAN, and BPAN.
60, 61, 62
  The other six
forms occur rarely.
63, 64
  NBIA can present over a wide age range from infancy to adulthood.
Forms commonly presenting in childhood are classic PKAN, PLAN (infantile neuroaxonal 
dystrophy and atypical neuroaxonal dystrophy sub-types), MPAN, BPAN, FAHN, Kufor-Rakeb 
syndrome, Woodhouse-Sakati syndrome, and CoPAN.
60-64
NBIA is characterized by progressive neurologic symptoms including dystonia, 
dysarthria, chorea, tremor, rigidity, and spasticity.
58, 59
  Other typical findings in patients with
NBIA include psychiatric abnormalities, optic atrophy, and retinal degeneration.  Some forms of 
NBIA have cognitive decline, but overall cognition is relatively spared.  Some forms have rapid 
progression while other forms have slow progression with periods of stability.  Status dystonicus 
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can be seen in patients with NBIA as well.  Complications and triggers of status dystonicus are 
discussed previously in this paper.  NBIA needs to be considered in children presenting with 
abnormal gait, dystonia, and/or dysarthria.   
A brain MRI is the most helpful test in determining the utility of further diagnostic 
testing for various forms of NBIA.  MRI findings consistent with brain iron accumulation are 
hypointense lesions in the globus pallidus and substantia nigra on T2 weighted images.  These 
lesions are isointense on T1 weighted images.
59
  A central region of hyperintensity in the globus 
pallidus with surrounding hypointensity on T2 weighted images, the so-called eye-of-the-tiger 
sign, is highly specific for pathogenic variants in the PANK2 gene.
65
  Other brain MRI findings 
commonly seen are generalized cerebral and cerebellar atrophy.  Clinical features and molecular 
genetic testing are used to give patients a specific diagnosis when possible. Molecular gene 
testing can be directed by MRI findings and clinical features pointing to a specific form of 
NBIA; however, multi-gene panels for NBIA are available and may be more cost effective when 
MRI findings and/or clinical features are not highly suggestive of a specific NBIA.
58, 59
   
Treatment for NBIA is supportive and includes standard therapies for seizures and 
spasticity.  Dietary support and management of dysphagia including gastrostomy tube placement 
is important for patients with NBIA.  Aspiration pneumonia is a common issue.  Baclofen (oral 
or intrathecal) and botulinum toxin are often used for dystonia treatment.  Levodopa has been 
used and is beneficial in rare cases though it’s efficacy decreases over time.58, 59  DBS may be 
beneficial for severe dystonia.
66
  Extreme episodes of dystonia can occur as the disease 
progresses and can be triggered by minor insults such as pain or infection.  Occult fractures also 
need to be considered in non-ambulatory patients with significant dystonia.
58
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Pediatric Neurotransmitter Diseases (PNDs) 
Neurotransmitter deficiency disorders presenting in childhood are a group of diseases 
caused by abnormalities in the production, transport, release, and reuptake of compounds that 
allow neurons to communicate effectively with other neurons or myocytes.  These conditions can 
be subdivided into categories based on the affected metabolic pathway: tetrahydrobiopterin, 
catecholamine (dopamine, norepinephrine, and epinephrine), and serotonin metabolism (with and 
without hyperphenylalaninemia), serine and glycine metabolism, pyridoxine metabolism, 
glutamate and gamma-aminobutyric acid (GABA) metabolism, and disorders with folate 
deficiency.
67
  Most of these conditions are inherited in an autosomal recessive pattern except for
autosomal dominant GTP cyclohydrolase 1 deficiency (a form of dopa-responsive dystonia or 
Segawa disease).   
Patients with PNDs typically present in infancy or early childhood, though presentation 
can occur at any age.  Common symptoms seen in this group of conditions are encephalopathy, 
developmental delay, developmental regression, central hypotonia, peripheral hypertonia, 
autonomic dysfunction, diurnal variation in symptoms with severity worsening later in the day, 
seizures, and abnormal movements (unilateral or asymmetric limb dystonia, progressive gait 
dysfunction, hypokinesia, rigidity, postural tremor, involuntary tongue thrusting, oculogyric 
crises, myoclonus, and chorea).  Although abnormal movements in young children often alert the 
clinician to the possibility of an underlying neurotransmitter deficiency disorder, there is 
significant variability in patient presentation and severity within these disorders.
67, 68
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PNDs are typically diagnosed based on biochemical abnormalities.  While serum and 
urine testing should be completed first, CSF collection and analysis is necessary for definitive 
diagnosis.  Initial biochemical testing should include plasma amino acids, urine organic acids, 
urine pterins, pipecolic acid, catecholamines, and serum prolactin.  The lumbar puncture for 
neurotransmitter deficiency testing requires a specific technique. CSF needs to be collected in 
specialized tubes in a certain order so the appropriate fraction can be analyzed for each 
metabolite and immediately frozen.  The following compounds can be analyzed: amino acids, 
catecholamine and serotonin metabolites (homovanillic acid, 5-hydroxyindoleacetic acid, 3-O-
methyldopa), pterins (neopterin, biopterin, primapterin, tetrahydrobiopterin), pyridoxal 5-
phosphate, 5-methyltetrahydrofolate, total and free GABA, gamma-hydroxybutyric acid, and 
homocarnosine.  Enzyme analysis and molecular gene testing for specific neurotransmitter 
deficiencies are also available for many of these disorders.
69
  It is anticipated that molecular 
genetic diagnosis will eventually supplant other diagnostic testing including CSF analysis.  
Movement disorders are predominant features in the following neurotransmitter 
deficiency diseases: 6-pyrvuvoyl-tetrahydropterin (PTPS) deficiency caused by pathogenic 
variants in the PTS gene; dihydropteridine reductase (DHPR) deficiency caused by pathogenic 
variants in the QDPR gene; autosomal recessive guanosine triphosphate cyclohydrolase 1 
(GTPCH1) deficiency caused by pathogenic variants in the GCH1 gene; autosomal dominant 
GTPCH1 deficiency (dopa-responsive dystonia or Segawa syndrome) also caused by pathogenic 
variants in the GCH1 gene; aromatic L-amino acid decarboxylase (AADC) deficiency caused by 
pathogenic variants in the DDC gene; sepiapterin reductase (SR) deficiency caused by 
pathogenic variants in the SPR gene; and tyrosine hydroxylase (TH) deficiency caused by 
pathogenic variants in the TH gene.
68-74
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It is important to recognize and quickly diagnose these conditions as several have specific 
treatments that can alter the disease course.  PTPS deficiency responds well to treatment if 
initiated prior to six months of age. Still, there is evidence that even later treatment may provide 
benefit.  Recommended treatments include tetrahydrobiopterin (BH4), levodopa, and 5-
hydroxytryptophan (5-HT)., Selegiline and entacapone can also be helpful.
73
  DHPR deficiency
also has a much better outcome with regards to movement abnormalities if treatment is initiated 
in the first six months; the cognitive delays do not respond as well to therapy.  5-HT and 
levodopa are standard treatments.  Selegiline, entacapone, and folinic acid may also be useful in 
combination with the standard treatments.  Autosomal recessive GTP cyclohydrolase 1 
deficiency patients are responsive to levodopa and BH4 replacement.  Motor symptoms 
commonly improve though not as well as in patients with the autosomal dominant form.  
Autosomal dominant GTP cyclohydrolase 1 deficiency (dopa responsive dystonia or Segawa 
disease) patients are very sensitive to levodopa therapy.  Typically, patients experience 
improvement within days of starting treatment and maximal improvement is achieved within a 
few months.  Dyskinesias may occur during dose titration, but they are not typically a limiting 
factor in treatment with slow medication increases.  AADC deficiency patients are typically 
treated with pyridoxine, dopamine agonists, and monoamine oxidase MAO inhibitors.  Some 
patients may respond to levodopa.  Overall, clinical improvements are limited despite available 
treatments for most patients.
74
  SR deficiency patients can see movement abnormality
improvement with levodopa therapy and 5-HT when used in combination with carbidopa.  
Second-line therapy includes monoamine oxidase inhibitors, serotonin reuptake inhibitors, 
melatonin, dopamine agonists, anticholinergics, and methylphenidate.  While the movement 
disorder symptoms can be improved, the developmental and intellectual delays are resistant to 
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treatment.
72
  TH deficiency patients respond completely to levodopa with a decarboxylase 
inhibitor such as carbidopa.  However, severe dyskinesias are common even with very low 
doses, especially in patients with more severe forms of the disease.  Selegiline or amantadine in 
combination with levodopa may help decrease dyskinesias.
70, 71
   
 
Conclusion 
Inborn errors of metabolism present with broadly recognizable phenotypes.  However, as 
biochemical and molecular testing improves and becomes more widely available new 
phenotypes and increased variability in severity for classic conditions becomes apparent.  
Review of the literature reveals that many IEM cause movement disorders and each movement 
disorder alone has poor specificity for a given IEM.  Early or mild cases of IEM with movement 
disorders can also mimic benign disorders such as Sandifer syndrome, benign hereditary chorea, 
and childhood tic disorders.  These variables can lead to delay in diagnosis.  Delayed diagnosis 
then prolongs time until the patient receives primary treatment for the underlying condition.  
Beyond the complexity of determining a specific metabolic abnormality in patients with 
movement disorders, decreased suspicion and under-recognition of both movement disorders and 
IEM also lead to patients developing severe movement disorders before primary treatment of 
their underlying condition is initiated.   
Currently, worsening or persistent movement disorders typically leads the clinician away 
from conditions with etiologies apart from IEM.  A movement disorder that behaves atypically 
also may point to an underlying IEM even without other signs and symptoms.  Progressively 
abnormal movements and the failure to respond to standard treatment serve as red flags, alerting 
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one to the need for further diagnostic inquiry.  Diagnostic evaluations for IEM-associated 
movement disorders are multifaceted.  They variously include neuroimaging, CSF, blood, and 
urine substrate and enzymatic evaluations, sometimes other tissue testing, and molecular (DNA) 
testing.  We expect that molecular testing will continue to supplant the other modalities over the 
next few years and lead to increasing broad phenotypes for individual disorders.   
Finally, treatment of children with IEM-associated movement disorders often has two 
facets:  symptomatic treatment of the abnormal movements and management of the underlying 
IEM or neurotransmitter disorder.  The most successful treatment usually occurs with early 
recognition of an underlying IEM that itself is amenable to therapy.  Even when that cannot be 
accomplished, early diagnosis and treatment of the IEM may still improve outcome. In either 
case, symptomatic treatment of the movement disorder often improves the child’s functional 
abilities and quality of life.  In the future, we hope for increased awareness of pediatric 
movement disorders and IEM that can cause movement disorders.  Improved access to testing 
providing a specific diagnosis and knowledge of primary and secondary treatments will also 
hopefully improve patient outcomes.      
Disclosure of interests: The authors have no commercial, proprietary, or financial interest in any 
products or companies described in this article. 
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Table 1 Metabolic Disorders Causing Chorea13, 36, 75 
Organic acidemias 
Propionic acidemia 
Methylmalonic acidemia 
Cobalamin C disease 
Glutaric aciduria, type 1 
Costeff syndrome (form of 3-methylglutaconic aciduria) 
D-2-hydroxyglutaric aciduria
Amino acid metabolism disorders 
Nonketotic hyperglycinemia 
Homocystinuria 
Phenylketonuria 
Urea cycle disorders 
Argininemia 
Mitochondrial disorders 
Pyruvate dehydrogenase complex deficiency 
Pyruvate carboxylase deficiency 
Leigh syndrome 
POLG-related disorders 
Purine metabolism disorders 
Lesch-Nyhan disease 
Adenosine deaminase deficiency 
Purine nucleoside phosphorylase deficiency 
Mineral metabolism and transport disorders 
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Wilson disease 
Neurodegeneration with brain iron accumulation 
Pantothenate kinase-associated neurodegeneration 
Lipid storage disorders 
GM1 gangliosidosis 
GM2 gangliosidosis 
Sandhoff disease (hexosaminidase A and B deficiency) 
Gaucher disease, type 2 
Metachromatic leukodystrophy 
Niemann Pick disease type C 
Disorders of creatine metabolism 
Cerebral creatine deficiency syndrome 2 (GAMT deficiency) 
Glucose transport disorder 
GLUT1 deficiency 
Neurotransmitter diseases 
6-pyrvuvoyl-tetrahydropterin deficiency
Dihydropteridine reductase deficiency 
Autosomal recessive guanosine-triphosphate cyclohydrolase 1 deficiency 
Aromatic L-amino acid decarboxylase 
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Table 2 Metabolic Disorders Causing Dystonia13, 36, 75 
Mitochondrial disorders 
Pyruvate dehydrogenase complex deficiency 
MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like 
episodes) 
NARP (neuropathy, ataxia, retinitis pigmentosa) 
Leigh syndrome 
Biotin-thiamine-responsive basal ganglia disease 
Primary coenzyme Q10 deficiency 
LHON-dystonia syndrome 
Mineral metabolism and transport disorders 
Wilson disease 
Neurodegeneration with brain iron accumulation 
Pantothenate kinase-associated neurodegeneration 
PLA2G6-associated neurodegeneration 
Mitochondrial-membrane protein-associated neurodegeneration 
Beta-propeller protein-associated neurodegeneration 
COASY protein-associated neurodegeneration 
Fatty acid hydroxylase-associated neurodegeneration 
Kufor-Rakeb syndrome 
Woodhouse-Sakati syndrome   
Organic acidemias 
Methylmalonic acidemia 
Propionic academia 
Glutaric aciduria, type 1 
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D-2-hydroxyglutaric aciduria
Homocystinuria 
Amino Acid metabolism disorders 
Tetrahydrobiopterin metabolism abnormalities 
Maple syrup urine disease 
Purine metabolism disorders 
Lesch-Nyhan disease 
Adenosine deaminase deficiency 
Purine nucleoside phosphorylase deficiency 
Lipid storage disorders 
GM1 gangliosidosis 
GM2 gangliosidosis (juvenile hexosaminidase A deficiency) 
Sandhoff disease (hexosaminidase A and B deficiency) 
Niemann Pick disease type C 
Metachromatic leukodystrophy 
Disorders of creatine metabolism 
Cerebral creatine deficiency syndrome type 2 (GAMT deficiency) 
Cerebral creatine deficiency syndrome type 1 (GATM deficiency) 
Glucose transport disorder 
GLUT1 deficiency 
Neuronal ceroid lipofuscinosis 
CLN1 (palmitoyl protein thioesterase 1 deficiency) 
CLN2 (tripeptidyl peptidase 1 deficiency) 
CLN3 (Batten disease) 
Neurotransmitter diseases 
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Tyrosine hydroxylase deficiency 
6-pyrvuvoyl-tetrahydropterin deficiency
Dihydropteridine reductase deficiency 
Autosomal recessive guanosine-triphosphate cyclohydrolase 1 deficiency 
Autosomal dominant guanosine-triphosphate cyclohydrolase 1 deficiency 
Aromatic L-amino acid decarboxylase deficiency 
Sepiapterin reductase deficiency 
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Table 3 Metabolic Disorders Causing Myoclonus13, 36, 75 
Lipid storage disorders 
GM1 gangliosidosis 
GM2 gangliosidosis (Tay Sachs disease/hexosaminidase A deficiency) 
Gaucher disease, type III 
Galactosialidosis, juvenile 
Amino acid metabolism disorders 
Nonketotic hyperglycinemia 
Organic acidurias 
Biotinidase deficiency 
Cobalamin deficiency (infantile) 
Urea cycle disorders 
Hyperornithinemia, hyperammonemia, homocitrullinuria syndrome 
Mitochondrial disease 
MERRF 
MELAS 
Alpers syndrome (POLG-related) 
Mineral metabolism and transport disorders 
Wilson disease 
Neurodegeneration with brain iron accumulation 
Kufor-Rakeb syndrome 
Disorders of creatine metabolism 
Cerebral creatine deficiency syndrome 2 (GAMT deficiency) 
Glucose transport disorder 
GLUT1 deficiency 
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Neurotransmitter diseases 
Tyrosine hydroxylase deficiency 
Aromatic L-amino acid decarboxylase deficiency 
Lysosomal storage disorders 
Sialidosis type 1 (neuramidase deficiency) 
Neuronal ceroid lipofuscinosis 
CLN1 (palmitoyl protein thioesterase 1 deficiency) 
CLN2 (tripeptidyl peptidase 1 deficiency) 
CLN3 (Batten disease) 
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Table 4 Metabolic Disorders Causing Tremor13, 36, 75 
Mineral metabolism and transport disorders 
Wilson disease 
Cystinosis 
Hartnup disease 
Neurodegeneration with brain iron accumulation 
Pantothenate kinase-associated neurodegeneration (PKAN)  
PLA2G6-associated neurodegeneration (PLAN) 
Mitochondrial-membrane protein-associated neurodegeneration (MPAN) 
Kufor-Rakeb syndrome 
Organic acidemias 
Biotinidase deficiency/multiple carboxylase deficiency 
Mitochondrial disease 
MELAS 
Kearns-Sayre syndrome 
Lipid storage disorders 
Niemann Pick disease type C 
Fucosidosis 
Glucose transport disorder 
GLUT1 deficiency 
Neurotransmitter diseases 
6-pyrvuvoyl-tetrahydropterin deficiency
Dihydropteridine reductase deficiency 
Autosomal recessive guanosine-triphosphate cyclohydrolase 1 deficiency 
Autosomal dominant guanosine-triphosphate cyclohydrolase 1 deficiency 
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Sepiapterin reductase deficiency 
Tyrosine hydroxylase deficiency 
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Table 5 Metabolic Disorders Causing Parkinsonism/Hypokinetic Rigid 
Syndrome13, 36, 75 
Mineral metabolism and transport disorders 
Wilson disease 
Neurodegeneration with brain iron accumulation 
Pantothenate kinase-associated neurodegeneration 
PLA2G6-associated neurodegeneration 
Mitochondrial-membrane protein-associated neurodegeneration 
Beta-propeller protein-associated neurodegeneration 
COASY protein-associated neurodegeneration 
Kufor-Rakeb syndrome 
Neurotransmitter disorders 
Tyrosine hydroxylase deficiency 
6-pyrvuvoyl-tetrahydropterin deficiency
Dihydropteridine reductase deficiency 
Autosomal recessive guanosine-triphosphate cyclohydrolase 1 deficiency 
Autosomal dominant guanosine-triphosphate cyclohydrolase 1 deficiency 
Aromatic L-amino acid decarboxylase deficiency 
Sepiapterin reductase deficiency 
Lysosomal storage disorders 
GM1 gangliosidosis 
Niemann-Pick disease type C 
Gaucher disease 
Neuronal ceroid lipofuscinosis 
Mitochondrial diseases 
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Leigh syndrome 
Biotin-thiamine-responsive basal ganglia disease 
Primary coenzyme Q10 deficiency 
Respiratory chain defects 
Pyruvate carboxylase deficiency 
Purine metabolism disorders 
Lesch Nyhan disease 
Glucose transport disorder 
GLUT1 deficiency 
Table 6 Neurodegeneration with Brain Iron Accumulation Forms
74
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Disease Name Associated Gene 
Pantothenate kinase-associated 
neurodegeneration (PKAN) 
PANK2 
PLA2G6-associated neurodegeneration 
(PLAN) 
PLA2G6 
Mitochondrial-membrane protein-associated 
neurodegeneration (MPAN) 
C19ORf12 
Beta-propeller protein-associated 
neurodegeneration (BPAN) 
WDR45 
COASY protein-associated 
neurodegeneration (CoPAN) 
COASY 
Fatty acid hydroxylase-associated 
neurodegeneration (FAHN) 
FA2H 
Kufor-Rakeb syndrome ATP13A2 
Woodhouse-Sakati syndrome DCAF17 
Aceruloplasminemia CP 
Neuroferritinopathy FTL 
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